Edition:
United States

Achaogen Inc (AKAO.OQ)

AKAO.OQ on NASDAQ Stock Exchange Global Market

11.81USD
21 May 2018
Change (% chg)

-- (--)
Prev Close
$11.81
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
316,812
52-wk High
$26.50
52-wk Low
$9.83

Chart for

About

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the... (more)

Overall

Beta: 0.88
Market Cap(Mil.): $557.71
Shares Outstanding(Mil.): 44.80
Dividend: --
Yield (%): --

Financials

  AKAO.OQ Industry Sector
P/E (TTM): -- 223.30 32.53
EPS (TTM): -3.31 -- --
ROI: -96.13 -8.07 12.63
ROE: -153.62 -10.87 14.50

BRIEF-Achaogen Q1 loss per share $1.06

* ACHAOGEN REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 04 2018

BRIEF-Achaogen Says FDA Advisory Committee Voted In Favor Of Plazomicin For Urinary Tract Infections

* ACHAOGEN ANNOUNCES FDA ADVISORY COMMITTEE VOTED UNANIMOUSLY IN FAVOR OF PLAZOMICIN FOR TREATMENT OF ADULTS WITH COMPLICATED URINARY TRACT INFECTIONS Source text for Eikon: Further company coverage:

May 02 2018

BRIEF-Achaogen Stock Trading Halted Today

* ACHAOGEN STOCK TRADING HALTED TODAY Source text for Eikon: Further company coverage:

May 02 2018

BRIEF-Achaogen Says FDA to Review Plazomicin By June 25

* ACHAOGEN ANNOUNCES DATE OF FDA ADVISORY COMMITTEE MEETING FOR PLAZOMICIN

Mar 21 2018

BRIEF-Robert Duggan Reports 14.2 Pct Stake In Achaogen Inc As Of March 12 Compared To A Stake Of 13.2 Pct As Of Dec 6

* ROBERT DUGGAN REPORTS 14.2 PERCENT STAKE IN ACHAOGEN INC AS OF MARCH 12 COMPARED TO A STAKE OF 13.2 PERCENT AS OF DECEMBER 6 -SEC FILING Source text: (http://bit.ly/2DoINbl) Further company coverage:

Mar 14 2018

BRIEF-Achaogen Enters Into New $50 Million Secured Credit Facility With Silicon Valley Bank

* ACHAOGEN ENTERS INTO NEW $50 MILLION SECURED CREDIT FACILITY WITH SILICON VALLEY BANK Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 01 2018

BRIEF-Achaogen Reports Q4 Loss Per Share $0.98

* ACHAOGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Feb 27 2018

BRIEF-Achaogen Announces Upgraded Status For Plazomicin Fill Manufacturer

* SAYS ‍FDA CLASSIFIED OUTCOME OF ITS Q4 2017 REINSPECTION OF PFIZER'S MCPHERSON FACILITY AS VOLUNTARY ACTION INDICATED​ Source text for Eikon: Further company coverage:

Jan 30 2018

BRIEF-Achaogen Announces Positive Top-Line Results From First Clinical Trial Of Orally-Administered Antibacterial Candidate C-Scape

* ACHAOGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM FIRST CLINICAL TRIAL OF ORALLY-ADMINISTERED ANTIBACTERIAL CANDIDATE C-SCAPE

Jan 02 2018

BRIEF-Achaogen Announces FDA Acceptance Of New Drug Application With Priority Review For Plazomicin

* ACHAOGEN ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION WITH PRIORITY REVIEW FOR PLAZOMICIN FOR TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND BLOODSTREAM INFECTIONS

Jan 02 2018

Earnings vs. Estimates